Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA21025QH" target="_blank" >RIV/61988987:17110/19:A21025QH - isvavai.cz</a>

Result on the web

<a href="https://www.sciencedirect.com/science/article/pii/S2152265019310420?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2152265019310420?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clml.2019.07.283" target="_blank" >10.1016/j.clml.2019.07.283</a>

Result language

angličtina

Original language name

Characterization of duvelisib in patients with refractory marginal zone lymphoma: data from the phase 2 DYNAMO trial

Original language description

Duvelisib, a first-in-class oral dual PI3-kinase-δ,γ inhibitor, is approved for the treatment of R/R CLL/SLL after ≥2 prior therapies and for follicular lymphoma (FL) after ≥2 prior systemic therapies. DYNAMO, a phase 2 trial that evaluated the safety and efficacy of duvelisib monotherapy in iNHL, including patients with marginal zone lymphoma (MZL). Patients were double refractory to rituximab-based therapy and chemotherapy or radioimmunotherapy.

Czech name

—

Czech description

—

Type

D - Article in proceedings

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Article name in the collection

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

ISBN

—

ISSN

2152-2650

e-ISSN

2152-2669

Number of pages

1

Pages from-to

312-312

Publisher name

—

Place of publication

Dallas, USA

Event location

Houston, Texas

Event date

Sep 11, 2019

Type of event by nationality

WRD - Celosvětová akce

UT code for WoS article

000483480700318